JACC Heart Failure Editor's Update, October 2018
OCTOBER 2018 MINI-FOCUS ISSUE: COMORBIDITIES
Abhinav Sharma, Lauren Cooper, et al look at the relationship between heart failure and diabetes and review the latest findings on glycemic management therapies. The prevalence of diabetes in heart failure patients and its association with poorer outcomes makes it critically important to understand the current thinking on the interaction and treatment of these diseases. The authors discuss the effectiveness and potential harm of various antihyperglycemic therapies, propose treatment strategies, and point to specific areas where further research is needed. Click below to read their State-of-the-Art Review:
Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus
Abhinav Sharma, Lauren B. Cooper, et al
Is a particular class of glucose-lowering drugs more effective in lowering the risk of hospitalization for heart failure among diabetics? Three classes of glucose-lowering drugs that have undergone cardiovascular evaluation in accordance with FDA guidance are compared through a systematic review and meta-analysis. The differences in effect on heart failure in patients with type 2 diabetes mellitus among these three classes of drugs are presented and analyzed. Click below to read a review of the evidence:
Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis
Caroline K. Kramer, Chang Ye, et al
Psychosocial factors are known to play a key role in the prognosis of patients with chronic heart failure. The OCEAN study provides some interesting insights into a possible role for omega-3 supplementation in treating heart failure patients suffering from depression. Wei Jiang, David Whellan, and their colleagues studied the effects of long-chain omega-3 fatty acids supplements in heart failure patients with depression and their findings help point the way to more effective treatment options and improvement in cognitive depressive symptoms. Click below to see the results:
Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial
Wei Jiang, David J. Whellan, et al
Respiratory infection is a known driver of morbidity in heart failure. Does vaccination make a difference in clinical outcomes? The authors looked at vaccination rates in hospitals participating in Get With The Guidelines for Heart Failure and examined the correlation of influenza and pneumococcal vaccination rates with quality measures and clinical outcomes. Their analysis provides information on the rate of vaccination and trends in this rate over time. Click below to learn more:
Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines–Heart Failure
Ankeet S. Bhatt, Li Liang, et al
MEET ASSOCIATE EDITOR David Whellan
Associate Editor David Whellan brings insight and perspective based on his in-depth knowledge and extensive experience in designing major clinical trials and conducting clinical research.
Dr. Whellan is the James C. Wilson Professor of Medicine at the Sidney Kimmel Medical College, the Senior Associate Provost for Clinical Research at Thomas Jefferson University and Jefferson Health, and Chief Operating Officer for the Partners in Innovation, Education and Research (PIER) Consortium©.
He graduated from Washington University School of Medicine in St. Louis, completed his internal medicine residency at the Hospital of the University of Pennsylvania, and completed his fellowship at Duke, where he also received a Masters of Health Science in Clinical Research. He spent 2 years on faculty at Duke before joining the Jefferson Heart Institute at Thomas Jefferson University.
Dr. Whellan’s research has focused on improving the care and treatment of patients with heart failure. He designed, implemented, and managed the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) Study, the largest investigator-initiated NHLBI-funded trial at that time. Based on the results of this landmark study, cardiac rehabilitation is now reimbursed by Medicare and other insurers for patients with HF. He continues his clinical research efforts as the PI or steering committee member for a number of clinical trials evaluating novel interventions and diagnostics for heart failure patients. He has authored more than 200 manuscripts, reviews, and book chapters.
As Senior Associate Provost for Clinical Research, Dr. Whellan has focused on designing the clinical research infrastructure required to perform cutting-edge, highly effective, and compliant clinical research. This work has resulted in the creation of the Jefferson Clinical Research Institute, which he oversees as the Executive Director. In his role as the Chief Operating Officer for the PIER Consortium©, he has leveraged his experience at Jefferson to build a unique clinical research network with 6 health systems in the Northeast.
3 Things People May Not Know about Me:
- Just like the first two associate editors that have been introduced, my musical skills were highly regarded among friends and family. I was the first kid in my class to start playing an instrument, the violin, at the age of 5. I peaked in first grade. I am the first child whose mother begged him to quit playing music—I was that good!
- I quit the violin to play tennis for my high school varsity team, and tennis has become a true passion of mine. My pilgrimage to the US Open is one of the top highlights for me each year. If you haven’t gone to the largest sporting event in the world, I highly recommend it, particularly the first week.
- One of my inspirations to improve the care of our patients and to build clinical research platforms for discovery is my daughter, who was born with congenital heart disease. She is living proof that the type of advances we are working on and the great care we provide makes a significant difference in our patients’ lives.
CALL FOR PAPERS
Focusing on the growing body of literature surrounding heart failure in women, JACC: Heart Failure is planning a special issue on this topic for March 2019. Learn more and submit your manuscript by November 30.